Dr. Bologa has been involved during the last 10 years in the data management, workflow processing, and the decision making for the discovery of new bioactive compounds in the Division of Biocomputing and Division of Translational Informatics at UNM. He has a broad background and more than 15 years experience in protein and small molecule modeling, screening informatics, chemoinformatics, and SAR for molecular discovery. He had significant contributions in developing and using new methods and tools for discovery of novel small bioactive molecules for integrins (LFA-1 and VLA-4), formyl peptide receptors (FPR-1 and FPRL1), for granularity induction in prostate cancer cell lines (LNCaP and PC3), for the anti-apoptotic member of the Bcl-2 family protein Bcl-B, and a very potent and selective agonist (G‑1) for a membrane estrogen receptor (GPR30). In summary, Dr. Bologa has a broad experience with developing and using innovative methods, tools, and platforms that support information intensive molecular discovery.
Research Areas
Drug Discovery (UMLS) | cheminformatics (UMLS) | data mining (UMLS) | drug design (UMLS) | translational research (UMLS)
Research Identifiers
ORCID iD:
https://orcid.org/0000-0003-2232-4244
Detecting Uncoded Self-Harm in Veterans’ Electronic Health Records Using Positive and Unlabeled Learning: Retrospective Cohort Study
Journal of Medical Internet Research
2026-06-04 | Journal article
DOI:
10.2196/89071
Contributors:
Praveen Kumar; Alexandria D Viszolay; Rajesh Upadhayaya; Fariha Moomtaheen; Donald R Greer (and 12 more)
Show more detail
Homepage URL
Contributors
Praveen Kumar
(Author)
Alexandria D Viszolay
(Author)
Rajesh Upadhayaya
(Author)
Fariha Moomtaheen
(Author)
Donald R Greer
(Author)
Cristian G Bologa
(Author)
Kristan A Schneider
(Author)
Sharon E Davis
(Author)
Michael E Matheny
(Author)
David van der Goes
(Author)
Gerardo Villarreal
(Author)
Yiliang Zhu
(Author)
Mauricio Tohen
(Author)
Scott A Malec
(Author)
Jeremy J Yang
(Author)
Elliot M Fielstein
(Author)
Christophe Gerard Lambert
(Author)
External identifiers
DOI:
10.2196/89071
Added
2026-06-04
Last modified
2026-06-04
Source:
Crossref
Crossref
COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS
2026-02-26 | Patent
Contributors:
Arterburn Jeffrey B; Bologa Cristian; Prossnitz Eric R
Show more detail
Homepage URL
Contributors
Arterburn Jeffrey B
(Other Inventor)
Bologa Cristian
(Other Inventor)
Prossnitz Eric R
(Other Inventor)
External identifiers
LENSID:
022-656-245-026-736
URI:
lens.org/022-656-245-026-736
PAT:
US 2026/0055074 A1
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
Effective spectrum-based antibiotic resistance index for monitoring resistance in Gram-negative bacilli
Antimicrobial Stewardship & Healthcare Epidemiology
2026 | Journal article
Contributors:
M. Cristina Vazquez Guillamet; Alice Bewley; Nicole J. Tarlton; Reid Goodman; Michael J. Durkin (and 7 more)
Show more detail
Homepage URL
Contributors
M. Cristina Vazquez Guillamet
(Author)
Alice Bewley
(Author)
Nicole J. Tarlton
(Author)
Reid Goodman
(Author)
Michael J. Durkin
(Author)
Michael Bernauer
(Author)
Meghan Brett
(Author)
Kevin Hsueh
(Author)
Cristian Bologa
(Author)
George Turabelidze
(Author)
Andrew Atkinson
(Author)
Victoria J. Fraser
(Author)
External identifiers
Added
2026-03-27
Last modified
2026-03-27
Source:
Crossref
Crossref
Compounds for selective binding to estrogen receptors alpha/beta relative to GPER/GPR30 and methods of treating disease states and conditions mediated through these receptors
2025-12-30 | Patent
Contributors:
Arterburn Jeffrey B; Bologa Cristian; Prossnitz Eric R
Show more detail
Homepage URL
Contributors
Arterburn Jeffrey B
(Other Inventor)
Bologa Cristian
(Other Inventor)
Prossnitz Eric R
(Other Inventor)
External identifiers
LENSID:
033-512-775-198-988
URI:
lens.org/033-512-775-198-988
PAT:
US 12509435 B2
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
Badapple 2.0: An Empirical Predictor of Compound Promiscuity, Updated, Modernized, and Enhanced for Explainability
2025-09-29 | Preprint
Contributors:
John Ringer; Christophe Lambert; Steven Bradfute; Cristian Bologa; Jeremy Yang
Show more detail
Homepage URL
Contributors
John Ringer
(Author)
Christophe Lambert
(Author)
Steven Bradfute
(Author)
Cristian Bologa
(Author)
Jeremy Yang
(Author)
External identifiers
Added
2025-09-30
Last modified
2026-01-21
Source:
Crossref
Crossref
Relationship between Rate of Hypernatremia Correction and Outcomes in Hospitalized Patients
Kidney360
2025-08 | Journal article
Contributors:
Gabriela Chacon-Palma; J. Pedro Teixeira; Igor Litvinovich; Cristian G. Bologa; Maria-Eleni Roumelioti (and 2 more)
Show more detail
Homepage URL
Contributors
Gabriela Chacon-Palma
(Author)
J. Pedro Teixeira
(Author)
Igor Litvinovich
(Author)
Cristian G. Bologa
(Author)
Maria-Eleni Roumelioti
(Author)
MingAn Yang
(Author)
Mark L. Unruh
(Author)
External identifiers
Added
2025-03-28
Last modified
2025-08-28
Source:
Crossref
Crossref
KG2ML: Integrating Knowledge Graphs and Positive Unlabeled Learning for Identifying Disease-Associated Genes
2025-03-17 | Preprint
Contributors:
Praveen Kumar; Vincent T. Metzger; Swastika T. Purushotham; Priyansh Kedia; Cristian G. Bologa (and 2 more)
Show more detail
Homepage URL
Contributors
Praveen Kumar
(Author)
Vincent T. Metzger
(Author)
Swastika T. Purushotham
(Author)
Priyansh Kedia
(Author)
Cristian G. Bologa
(Author)
Christophe G. Lambert
(Author)
Jeremy J. Yang
(Author)
External identifiers
Added
2025-03-20
Last modified
2025-10-23
Source:
Crossref
Crossref
Detecting Opioid Use Disorder in Health Claims Data With Positive Unlabeled Learning
IEEE Journal of Biomedical and Health Informatics
2025-02 | Journal article
Contributors:
Praveen Kumar; Fariha Moomtaheen; Scott A. Malec; Jeremy J. Yang; Cristian G. Bologa (and 9 more)
Show more detail
Homepage URL
Contributors
Praveen Kumar
(Author)
Fariha Moomtaheen
(Author)
Scott A. Malec
(Author)
Jeremy J. Yang
(Author)
Cristian G. Bologa
(Author)
Kristan A Schneider
(Author)
Yiliang Zhu
(Author)
Mauricio Tohen
(Author)
Gerardo Villarreal
(Author)
Douglas J. Perkins
(Author)
Elliot M. Fielstein
(Author)
Sharon E. Davis
(Author)
Michael E. Matheny
(Author)
Christophe G. Lambert
(Author)
External identifiers
Added
2025-02-10
Last modified
2025-02-10
Source:
Crossref
Crossref
TIN-X version 3: update with expanded dataset and modernized architecture for enhanced illumination of understudied targets
PeerJ
2024-06-25 | Journal article
DOI:
10.7717/peerj.17470
Contributors:
Vincent T. Metzger; Daniel C. Cannon; Jeremy J. Yang; Stephen L. Mathias; Cristian G. Bologa (and 9 more)
Show more detail
Homepage URL
Contributors
Vincent T. Metzger
(Author)
Daniel C. Cannon
(Author)
Jeremy J. Yang
(Author)
Stephen L. Mathias
(Author)
Cristian G. Bologa
(Author)
Anna Waller
(Author)
Stephan C. Schürer
(Author)
Dušica Vidović
(Author)
Keith J. Kelleher
(Author)
Timothy K. Sheils
(Author)
Lars Juhl Jensen
(Author)
Christophe G. Lambert
(Author)
Tudor I. Oprea
(Author)
Jeremy S. Edwards
(Author)
External identifiers
DOI:
10.7717/peerj.17470
Added
2024-06-25
Last modified
2024-06-25
Source:
Crossref
Crossref
Preclinical evaluation of the novel curcumin Analogue AKT-100 demonstrates therapeutic effectiveness in p53-mutated cancer cells
Cancer Research
2024-03-22 | Journal article
Contributors:
Kimberly K. Leslie; Jamie L. Padilla; Geneva L. Williams; Hua-Ying Fan; Cristian G. Bologa (and 6 more)
Show more detail
Contributors
Kimberly K. Leslie
(Author)
Jamie L. Padilla
(Author)
Geneva L. Williams
(Author)
Hua-Ying Fan
(Author)
Cristian G. Bologa
(Author)
Eric R. Prossnitz
(Author)
Jun-Yong Choe
(Author)
Lane E. Smith
(Author)
Alexander Goss
(Author)
Robert J. Lake
(Author)
Avinash D. Sahu
(Author)
External identifiers
ISSN:
1538-7445
Abstract
Abstract
Among the myriad of molecular alterations associated with cancer, loss of the normal tumor suppressive functions of p53, the “guardian of the genome,” is the most consistent. Thus, the possibility of targeting oncogenic, mutant p53 proteins has long been a therapeutic goal. However, that aspiration has not been fully realized, leaving patients vulnerable to aggressive disease that is resistant to chemotherapy and to targeted agents such as PARP inhibitors and immunotherapy owing to the loss of wild type p53 functionality and the gain of new oncogenic functions when mutant p53 is expressed. An effective therapeutic strategy is urgently needed for p53 mutant cancers, and our team is developing novel analogues of curcumin with the potential to convert mutant p53 to a wild type conformation and restore its tumor suppressive functions. In this study, we investigated the effects of AKT-100, which was developed from the parent molecule and curcumin analogue HO-3867. Effects were compared to another drug believed to reactivate p53 functionality, APR-246, using CyQUANT IC50 cell proliferation assays and bulk and single cell RNA sequencing. Structural analyses are underway investigating the specific sites of interaction of AKT-100 with various mutant forms of p53. Our findings indicate that, first, AKT-100 exhibits impressive cell killing in multiple ovarian and serous endometrial cancer cells at concentrations ranging from 100-300 nM and is synergistic with the PARP inhibitor olaparib. Second, RNA sequencing demonstrates the reactivation of wild type p53 genes associated with normal cell cycle regulation (induction of CDKN1A encoding p21 and GADD45A), apoptosis (induction of PMAIP1 encoding Noxa and DR5 encoding Death Receptor 5), and the inhibition of DNA replication and multiple alternative mechanisms of DNA repair employed by malignant cells. Third, RNA sequencing indicates that AKT-100 acts through both p53-dependent and independent pathways to inhibit cancer cell proliferation. Gene expression is impacted in ways that portend a therapeutic effect as well as highlight potential resistance pathways (e.g. significant induction of PLK5 encoding polo like kinase 5) that can be further targeted to create synthetic lethal drug combinations with AKT-100 chosen specifically to target the various mutant forms of p53. Taken together, these results identify novel curcumin analogues in early development with the potential to improve therapy for p53 mutant cancers. Through this strategy it is also possible to identify and block resistance pathways that are activated by different forms of mutant p53 in response to AKT-100 and to create synthetic lethal precision drug combinations.
Citation Format: Kimberly K. Leslie, Jamie L. Padilla, Geneva L. Williams, Hua-Ying Fan, Cristian G. Bologa, Eric R. Prossnitz, Jun-Yong Choe, Lane E. Smith, Alexander Goss, Robert J. Lake, Avinash D. Sahu. Preclinical evaluation of the novel curcumin Analogue AKT-100 demonstrates therapeutic effectiveness in p53-mutated cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4641.
Among the myriad of molecular alterations associated with cancer, loss of the normal tumor suppressive functions of p53, the “guardian of the genome,” is the most consistent. Thus, the possibility of targeting oncogenic, mutant p53 proteins has long been a therapeutic goal. However, that aspiration has not been fully realized, leaving patients vulnerable to aggressive disease that is resistant to chemotherapy and to targeted agents such as PARP inhibitors and immunotherapy owing to the loss of wild type p53 functionality and the gain of new oncogenic functions when mutant p53 is expressed. An effective therapeutic strategy is urgently needed for p53 mutant cancers, and our team is developing novel analogues of curcumin with the potential to convert mutant p53 to a wild type conformation and restore its tumor suppressive functions. In this study, we investigated the effects of AKT-100, which was developed from the parent molecule and curcumin analogue HO-3867. Effects were compared to another drug believed to reactivate p53 functionality, APR-246, using CyQUANT IC50 cell proliferation assays and bulk and single cell RNA sequencing. Structural analyses are underway investigating the specific sites of interaction of AKT-100 with various mutant forms of p53. Our findings indicate that, first, AKT-100 exhibits impressive cell killing in multiple ovarian and serous endometrial cancer cells at concentrations ranging from 100-300 nM and is synergistic with the PARP inhibitor olaparib. Second, RNA sequencing demonstrates the reactivation of wild type p53 genes associated with normal cell cycle regulation (induction of CDKN1A encoding p21 and GADD45A), apoptosis (induction of PMAIP1 encoding Noxa and DR5 encoding Death Receptor 5), and the inhibition of DNA replication and multiple alternative mechanisms of DNA repair employed by malignant cells. Third, RNA sequencing indicates that AKT-100 acts through both p53-dependent and independent pathways to inhibit cancer cell proliferation. Gene expression is impacted in ways that portend a therapeutic effect as well as highlight potential resistance pathways (e.g. significant induction of PLK5 encoding polo like kinase 5) that can be further targeted to create synthetic lethal drug combinations with AKT-100 chosen specifically to target the various mutant forms of p53. Taken together, these results identify novel curcumin analogues in early development with the potential to improve therapy for p53 mutant cancers. Through this strategy it is also possible to identify and block resistance pathways that are activated by different forms of mutant p53 in response to AKT-100 and to create synthetic lethal precision drug combinations.
Citation Format: Kimberly K. Leslie, Jamie L. Padilla, Geneva L. Williams, Hua-Ying Fan, Cristian G. Bologa, Eric R. Prossnitz, Jun-Yong Choe, Lane E. Smith, Alexander Goss, Robert J. Lake, Avinash D. Sahu. Preclinical evaluation of the novel curcumin Analogue AKT-100 demonstrates therapeutic effectiveness in p53-mutated cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4641.
Added
2026-08-12
Last modified
2026-08-12
Source:
Cristian G Bologa
Cristian G Bologa
Seeking novel therapeutic targets in oncology using machine learning
Cancer Research
2024-03-22 | Journal article
Contributors:
Mohammed Quazi; Suman Sirimulla; Cristian G. Bologa; Alexei Pushechnikov; Nikolay Savchuk (and 1 more)
Show more detail
Contributors
Mohammed Quazi
(Author)
Suman Sirimulla
(Author)
Cristian G. Bologa
(Author)
Alexei Pushechnikov
(Author)
Nikolay Savchuk
(Author)
Tudor Ionel Oprea
(Author)
External identifiers
ISSN:
1538-7445
Abstract
Abstract
We developed 42 machine learning models using Knowledge Graphs (KGML), informed by data from Pharos (1), based on major resources like DepMap (2), Reactome (3), and STRING (4). Focused on 41 blood cancers, we utilized cancer-specific positive genes and 440 shared negative genes, using metapath and XGBoost (5).
Analysis of the top 500 genes from each model revealed 3,842 genes strongly linked to cancers, with 519 classified as “Tchem,”i.e., small molecule modulators are known (6). We focused on Tchem proteins given the notion that small molecules perturbing these proteins are already known, which accelerates drug discovery. A separate, 1SVM (one-class support vector machine) model was built using mode-of-action drug targets (6) (Tclin, N = 704) as input. This 42nd model evaluates the likelihood that a gene shares the characteristics of Tclin targets (“Tclin-like”). Of the 519 Tchem genes, 132 have “Tclin-like” probability above 50%. The top five “Tclin-like” genes are GAPDH, AKT1, HRAS, TLR4 and TP53, respectively; their role in cancer is well studied.
Our focus shifted to 19 genes that have limited or no known cancer associations, as evaluated by the DISEASES platform (7) - see Table 1. Three genes (LPAR5, GPR18 and FCER2) are associated with primary bone diffuse large B cell lymphoma, and 2 (ADCY1 and PLD1) with B cell prolymphocytic leukemia. Additional studies may elucidate their role in these malignancies. Five genes (IRAK3, EPHB1, ITPKB, ACVR2B and CAMK2D) are predicted to be relevant in 10 or more blood cancers. Machine learning may uncover overlooked, but potentially promising drug targets for leukemias, lymphomas and myelomas.
References 1. Kelleher KJ, et al. Nucl Acids Res. 2023; 51:D1405-16.2. Tsherniak A, et al. Cell. 2017; 170:564-76.e16.3. Gillespie M, et al. Nucl Acids Res. 2022; 50:D687-92.4. Szklarczyk D, et al. Nucl Acids Res. 2023; 51:D638-46.5. Binder J, et al. Commun Biol. 2022; 5:125.6. Oprea TI, et al. Nat Rev Drug Discov. 2018; 17:317-32.7. Grissa D, et al. Database. 2022; 2022:baac019.
Table 1: “Tclin-like” targets lacking known cancer associations. Gene 41 Cancer counts Disease names LPAR5 1 primary bone diffuse large B cell lymphoma ADCY1 1 B cell prolymphocytic leukaemia ITPKB 15 PLD1 1 B cell prolymphocytic leukaemia PRKCE 2 hepatosplenic T cell lymphoma; acute leukaemia of ambiguous lineage EPHB1 17 GPR18 1 primary bone diffuse large B cell lymphoma FRK 3 chronic myeloid leukaemia; acute myeloid leukaemia therapy related; NK cell leukaemia CAMK2D 13 IRAK3 20 TRPV4 1 primary central nervous system lymphoma ACVR2B 14 TRPC6 1 Hodgkin lymphoma FCER2 1 primary bone diffuse large B cell lymphoma GRM8 1 acute myeloid leukaemia therapy related CAMK2A 1 hepatosplenic T cell lymphoma BLK 4 ADORA3 1 acute leukaemic transformation of myeloproliferative neoplasm PIM1 8
Citation Format: Mohammed Quazi, Suman Sirimulla, Cristian G. Bologa, Alexei Pushechnikov, Nikolay Savchuk, Tudor Ionel Oprea. Seeking novel therapeutic targets in oncology using machine learning [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3535.
We developed 42 machine learning models using Knowledge Graphs (KGML), informed by data from Pharos (1), based on major resources like DepMap (2), Reactome (3), and STRING (4). Focused on 41 blood cancers, we utilized cancer-specific positive genes and 440 shared negative genes, using metapath and XGBoost (5).
Analysis of the top 500 genes from each model revealed 3,842 genes strongly linked to cancers, with 519 classified as “Tchem,”i.e., small molecule modulators are known (6). We focused on Tchem proteins given the notion that small molecules perturbing these proteins are already known, which accelerates drug discovery. A separate, 1SVM (one-class support vector machine) model was built using mode-of-action drug targets (6) (Tclin, N = 704) as input. This 42nd model evaluates the likelihood that a gene shares the characteristics of Tclin targets (“Tclin-like”). Of the 519 Tchem genes, 132 have “Tclin-like” probability above 50%. The top five “Tclin-like” genes are GAPDH, AKT1, HRAS, TLR4 and TP53, respectively; their role in cancer is well studied.
Our focus shifted to 19 genes that have limited or no known cancer associations, as evaluated by the DISEASES platform (7) - see Table 1. Three genes (LPAR5, GPR18 and FCER2) are associated with primary bone diffuse large B cell lymphoma, and 2 (ADCY1 and PLD1) with B cell prolymphocytic leukemia. Additional studies may elucidate their role in these malignancies. Five genes (IRAK3, EPHB1, ITPKB, ACVR2B and CAMK2D) are predicted to be relevant in 10 or more blood cancers. Machine learning may uncover overlooked, but potentially promising drug targets for leukemias, lymphomas and myelomas.
References 1. Kelleher KJ, et al. Nucl Acids Res. 2023; 51:D1405-16.2. Tsherniak A, et al. Cell. 2017; 170:564-76.e16.3. Gillespie M, et al. Nucl Acids Res. 2022; 50:D687-92.4. Szklarczyk D, et al. Nucl Acids Res. 2023; 51:D638-46.5. Binder J, et al. Commun Biol. 2022; 5:125.6. Oprea TI, et al. Nat Rev Drug Discov. 2018; 17:317-32.7. Grissa D, et al. Database. 2022; 2022:baac019.
Table 1: “Tclin-like” targets lacking known cancer associations. Gene 41 Cancer counts Disease names LPAR5 1 primary bone diffuse large B cell lymphoma ADCY1 1 B cell prolymphocytic leukaemia ITPKB 15 PLD1 1 B cell prolymphocytic leukaemia PRKCE 2 hepatosplenic T cell lymphoma; acute leukaemia of ambiguous lineage EPHB1 17 GPR18 1 primary bone diffuse large B cell lymphoma FRK 3 chronic myeloid leukaemia; acute myeloid leukaemia therapy related; NK cell leukaemia CAMK2D 13 IRAK3 20 TRPV4 1 primary central nervous system lymphoma ACVR2B 14 TRPC6 1 Hodgkin lymphoma FCER2 1 primary bone diffuse large B cell lymphoma GRM8 1 acute myeloid leukaemia therapy related CAMK2A 1 hepatosplenic T cell lymphoma BLK 4 ADORA3 1 acute leukaemic transformation of myeloproliferative neoplasm PIM1 8
Citation Format: Mohammed Quazi, Suman Sirimulla, Cristian G. Bologa, Alexei Pushechnikov, Nikolay Savchuk, Tudor Ionel Oprea. Seeking novel therapeutic targets in oncology using machine learning [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3535.
Added
2026-08-12
Last modified
2026-08-12
Source:
Cristian G Bologa
Cristian G Bologa
Toxicology knowledge graph for structural birth defects
Communications Medicine
2023-07-17 | Journal article
Contributors:
John Erol Evangelista; Daniel J. B. Clarke; Zhuorui Xie; Giacomo B. Marino; Vivian Utti (and 13 more)
Show more detail
Homepage URL
Contributors
John Erol Evangelista
(Author)
Daniel J. B. Clarke
(Author)
Zhuorui Xie
(Author)
Giacomo B. Marino
(Author)
Vivian Utti
(Author)
Sherry L. Jenkins
(Author)
Taha Mohseni Ahooyi
(Author)
Cristian G. Bologa
(Author)
Jeremy J. Yang
(Author)
Jessica L. Binder
(Author)
Praveen Kumar
(Author)
Christophe G. Lambert
(Author)
Jeffrey S. Grethe
(Author)
Eric Wenger
(Author)
Deanne Taylor
(Author)
Tudor I. Oprea
(Author)
Bernard de Bono
(Author)
Avi Ma’ayan
(Author)
External identifiers
Added
2023-07-17
Last modified
2023-07-17
Source:
Crossref
Crossref
COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS
2023-02-09 | Patent
Contributors:
Arterburn Jeffrey B; Bologa Cristian; Prossnitz Eric R
Show more detail
Homepage URL
Contributors
Arterburn Jeffrey B
(Other Inventor)
Bologa Cristian
(Other Inventor)
Prossnitz Eric R
(Other Inventor)
External identifiers
LENSID:
062-789-339-332-339
URI:
lens.org/062-789-339-332-339
PAT:
US 2023/0039502 A1
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
Outcomes of Hospital-Acquired Hypernatremia
Source:
Web of Science
Web of Science
Hypernatremia in Hospitalized Patients: A Large Population-Based Study
Kidney360
2022-07-28 | Journal article
Contributors:
Soraya Arzhan; Maria-Eleni Roumelioti; Igor Litvinovich; Cristian G. Bologa; Orrin B. Myers (and 1 more)
Show more detail
Homepage URL
Contributors
Soraya Arzhan
(Author)
Maria-Eleni Roumelioti
(Author)
Igor Litvinovich
(Author)
Cristian G. Bologa
(Author)
Orrin B. Myers
(Author)
Mark L. Unruh
(Author)
External identifiers
Added
2022-05-11
Last modified
2022-07-28
Source:
Crossref
Crossref
CACHE (Critical Assessment of Computational Hit-finding Experiments): A public–private partnership benchmarking initiative to enable the development of computational methods for hit-finding
Nature Reviews Chemistry
2022-02-15 | Journal article
Contributors:
Suzanne Ackloo; Rima Al-awar; Rommie E. Amaro; Cheryl H. Arrowsmith; Hatylas Azevedo (and 36 more)
Show more detail
Homepage URL
Contributors
Suzanne Ackloo
(Author)
Rima Al-awar
(Author)
Rommie E. Amaro
(Author)
Cheryl H. Arrowsmith
(Author)
Hatylas Azevedo
(Author)
Robert A. Batey
(Author)
Yoshua Bengio
(Author)
Ulrich A. K. Betz
(Author)
Cristian G. Bologa
(Author)
John D. Chodera
(Author)
Wendy D. Cornell
(Author)
Ian Dunham
(Author)
Gerhard F. Ecker
(Author)
Kristina Edfeldt
(Author)
Aled M. Edwards
(Author)
Michael K. Gilson
(Author)
Claudia R. Gordijo
(Author)
Gerhard Hessler
(Author)
Alexander Hillisch
(Author)
Anders Hogner
(Author)
John J. Irwin
(Author)
Johanna M. Jansen
(Author)
Daniel Kuhn
(Author)
Andrew R. Leach
(Author)
Alpha A. Lee
(Author)
Uta Lessel
(Author)
Maxwell R. Morgan
(Author)
John Moult
(Author)
Ingo Muegge
(Author)
Tudor I. Oprea
(Author)
Benjamin G. Perry
(Author)
Patrick Riley
(Author)
Sophie A. L. Rousseaux
(Author)
Kumar Singh Saikatendu
(Author)
Vijayaratnam Santhakumar
(Author)
Matthieu Schapira
(Author)
Cora Scholten
(Author)
Matthew H. Todd
(Author)
Masoud Vedadi
(Author)
Andrea Volkamer
(Author)
Timothy M. Willson
(Author)
External identifiers
Added
2022-02-15
Last modified
2022-11-24
Source:
Crossref
Crossref
Machine learning prediction and tau-based screening identifies potential Alzheimer’s disease genes relevant to immunity
Communications Biology
2022-02-11 | Journal article
Contributors:
Jessica Binder; Oleg Ursu; Cristian Bologa; Shanya Jiang; Nicole Maphis (and 8 more)
Show more detail
Homepage URL
Contributors
Jessica Binder
(Author)
Oleg Ursu
(Author)
Cristian Bologa
(Author)
Shanya Jiang
(Author)
Nicole Maphis
(Author)
Somayeh Dadras
(Author)
Devon Chisholm
(Author)
Jason Weick
(Author)
Orrin Myers
(Author)
Praveen Kumar
(Author)
Jeremy J. Yang
(Author)
Kiran Bhaskar
(Author)
Tudor I. Oprea
(Author)
External identifiers
Added
2022-02-11
Last modified
2022-10-23
Source:
Crossref
Crossref
COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30
2021-03-04 | Patent
Contributors:
Arterburn Jeffrey; Bologa Cristian; Prossnitz Eric
Show more detail
Homepage URL
Contributors
Arterburn Jeffrey
(Other Inventor)
Bologa Cristian
(Other Inventor)
Prossnitz Eric
(Other Inventor)
External identifiers
LENSID:
168-701-643-101-505
URI:
lens.org/168-701-643-101-505
PAT:
WO 2021/041107 A1
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
Human GLUT5 specific inhibitors and methods of treatment
2020-11-03 | Patent
Contributors:
Bologa Cristian George; Choe Jun-yong; Iancu Cristina; Oprea Tudor I; Ursu Oleg
Show more detail
Homepage URL
Contributors
Bologa Cristian George
(Other Inventor)
Choe Jun-yong
(Other Inventor)
Iancu Cristina
(Other Inventor)
Oprea Tudor I
(Other Inventor)
Ursu Oleg
(Other Inventor)
External identifiers
LENSID:
084-116-758-254-605
URI:
lens.org/084-116-758-254-605
PAT:
US 10822325 B2
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
ANTI-PARASITIC PROPERTIES FOR NEEM DERIVATIVES: POTENTIAL NOVEL THERAPEUTIC OPTIONS FOR CONTROLLING RESISTANT <i>PLASMODIUM FALCIPARUM</i> MALARIA
Source:
Web of Science
Web of Science
HUMAN GLUT5 SPECIFIC INHIBITORS AND METHODS OF TREATMENT
2018-06-21 | Patent
Contributors:
Bologa Cristian George; Choe Jun-yong; Iancu Cristina; Oprea Tudor I; Ursu Oleg
Show more detail
Homepage URL
Contributors
Bologa Cristian George
(Other Inventor)
Choe Jun-yong
(Other Inventor)
Iancu Cristina
(Other Inventor)
Oprea Tudor I
(Other Inventor)
Ursu Oleg
(Other Inventor)
External identifiers
LENSID:
037-489-887-627-76X
URI:
lens.org/037-489-887-627-76X
PAT:
US 2018/0170897 A1
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
THE ASSOCIATION OF PALLIATIVE CARE SERVICES IN ALCOHOLIC HEPATITIS WITH TREATMENT, INTERVENTIONS AND END-OF-LIFE QUALITY
Source:
Web of Science
Web of Science
HUMAN GLUT5 SPECIFIC INHIBITORS AND METHODS OF TREATMENT
2016-12-15 | Patent
Contributors:
Bologa Cristian George; Choe Jun-yong; Iancu Cristina; Oprea Tudor I; Ursu Oleg
Show more detail
Homepage URL
Contributors
Bologa Cristian George
(Other Inventor)
Choe Jun-yong
(Other Inventor)
Iancu Cristina
(Other Inventor)
Oprea Tudor I
(Other Inventor)
Ursu Oleg
(Other Inventor)
External identifiers
LENSID:
063-814-495-515-75X
URI:
lens.org/063-814-495-515-75X
PAT:
WO 2016/201214 A1
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair
Journal of Biomolecular Screening
2015-10-06 | Journal article
Contributors:
Y. Wu; S. R. Stauffer; R. L. Stanfield; P. H. Tapia; O. Ursu (and 13 more)
Show more detail
Contributors
Y. Wu
(Author)
S. R. Stauffer
(Author)
R. L. Stanfield
(Author)
P. H. Tapia
(Author)
O. Ursu
(Author)
G. W. Fisher
(Author)
C. Szent-Gyorgyi
(Author)
A. Evangelisti
(Author)
A. Waller
(Author)
J. J. Strouse
(Author)
M. B. Carter
(Author)
C. Bologa
(Author)
K. Gouveia
(Author)
M. Poslusney
(Author)
A. S. Waggoner
(Author)
C. W. Lindsley
(Author)
J. W. Jarvik
(Author)
L. A. Sklar
(Author)
External identifiers
DOI:
10.1177/1087057115609145
Added
2016-03-29
Last modified
2022-05-24
Source:
Crossref Metadata Search
Crossref Metadata Search
Therapeutic Options and Emerging Alternatives for Multidrug Resistant Staphylococcal Infections
CPD
2015-04 | Journal article
Contributors:
Maria Magana; Anastasios Ioannidis; Emmanouil Magiorkinis; Oleg Ursu; Cristian Bologa (and 3 more)
Show more detail
Contributors
Maria Magana
(Author)
Anastasios Ioannidis
(Author)
Emmanouil Magiorkinis
(Author)
Oleg Ursu
(Author)
Cristian Bologa
(Author)
Stylianos Chatzipanagiotou
(Author)
Michael Hamblin
(Author)
George Tegos
(Author)
External identifiers
DOI:
10.2174/1381612821666150310101851
Added
2016-03-29
Last modified
2022-05-24
Source:
Crossref Metadata Search
Crossref Metadata Search
Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis
Proc Natl Acad Sci USA
2015-02-06 | Journal article
Contributors:
Dawn R. Christianson; Andrey S. Dobroff; Bettina Proneth; Amado J. Zurita; Ahmad Salameh (and 14 more)
Show more detail
Contributors
Dawn R. Christianson
(Author)
Andrey S. Dobroff
(Author)
Bettina Proneth
(Author)
Amado J. Zurita
(Author)
Ahmad Salameh
(Author)
Eleonora Dondossola
(Author)
Jun Makino
(Author)
Cristian G. Bologa
(Author)
Tracey L. Smith
(Author)
Virginia J. Yao
(Author)
Tiffany L. Calderone
(Author)
David J. O'Connell
(Author)
Tudor I. Oprea
(Author)
Kazunori Kataoka
(Author)
Dolores J. Cahill
(Author)
Jeffrey E. Gershenwald
(Author)
Richard L. Sidman
(Author)
Wadih Arap
(Author)
Renata Pasqualini
(Author)
External identifiers
DOI:
10.1073/pnas.1424994112
Added
2016-03-29
Last modified
2022-05-24
Source:
Crossref Metadata Search
Crossref Metadata Search
Ligand-Directed Profiling of Organelles with Internalizing Phage Libraries
Current Protocols in Protein Science
2015-02-02 | Other
Contributors:
Andrey S. Dobroff; Roberto Rangel; Liliana Guzman-Roja; Carolina C. Salmeron; Juri G. Gelovani (and 6 more)
Show more detail
Contributors
Andrey S. Dobroff
(Author)
Roberto Rangel
(Author)
Liliana Guzman-Roja
(Author)
Carolina C. Salmeron
(Author)
Juri G. Gelovani
(Author)
Richard L. Sidman
(Author)
Cristian G. Bologa
(Author)
Tudor I. Oprea
(Author)
C. Jeffrey Brinker
(Author)
Renata Pasqualini
(Author)
Wadih Arap
(Author)
External identifiers
DOI:
10.1002/0471140864.ps3004s79
Added
2016-03-29
Last modified
2022-05-24
Source:
Crossref Metadata Search
Crossref Metadata Search
Defining the microbial effluxome in the content of the host-microbiome interaction
Front. Pharmacol.
2015-02 | Journal article
Contributors:
Anastasios Ioannidis; Maria Magana; Cristian G. Bologa; Tudor I. Oprea; Ian T. Paulsen (and 1 more)
Show more detail
Contributors
Anastasios Ioannidis
(Author)
Maria Magana
(Author)
Cristian G. Bologa
(Author)
Tudor I. Oprea
(Author)
Ian T. Paulsen
(Author)
George P. Tegos
(Author)
External identifiers
DOI:
10.3389/fphar.2015.00031
Added
2016-03-29
Last modified
2022-05-24
Source:
Crossref Metadata Search
Crossref Metadata Search
CHEMICAL AND BIOLOGICAL DESCRIPTOR INTEGRATION IMPROVES COMPUTATIONAL MODELING OF <i>IN VIVO</i> RAT TOXICITY
Source:
Web of Science
Web of Science
FRET detection of lymphocyte function-associated antigen-1 conformational extension
Molecular Biology of the Cell
2014-11-05 | Journal article
Contributors:
A. Chigaev; Y. Smagley; M. K. Haynes; O. Ursu; C. G. Bologa (and 8 more)
Show more detail
Contributors
A. Chigaev
(Author)
Y. Smagley
(Author)
M. K. Haynes
(Author)
O. Ursu
(Author)
C. G. Bologa
(Author)
L. Halip
(Author)
T. Oprea
(Author)
A. Waller
(Author)
M. B. Carter
(Author)
Y. Zhang
(Author)
W. Wang
(Author)
T. Buranda
(Author)
L. A. Sklar
(Author)
External identifiers
DOI:
10.1091/mbc.e14-06-1050
Added
2016-03-29
Last modified
2022-05-24
Source:
Crossref Metadata Search
Crossref Metadata Search
A high throughput flow cytometric assay platform targeting transporter inhibition
Drug Discovery Today: Technologies
2014-06 | Journal article
Contributors:
George P. Tegos; Annette M. Evangelisti; J. Jacob Strouse; Oleg Ursu; Cristian Bologa (and 1 more)
Show more detail
Contributors
George P. Tegos
(Author)
Annette M. Evangelisti
(Author)
J. Jacob Strouse
(Author)
Oleg Ursu
(Author)
Cristian Bologa
(Author)
Larry A. Sklar
(Author)
External identifiers
DOI:
10.1016/j.ddtec.2014.03.010
Added
2016-03-29
Last modified
2022-05-24
Source:
Crossref Metadata Search
Crossref Metadata Search
Exploring the biological promiscuity of high-throughput screening hits through DFT calculations
Bioorganic & Medicinal Chemistry
2014-04 | Journal article
Contributors:
Ramona Curpăn; Sorin Avram; Robert Vianello; Cristian Bologa
Show more detail
Homepage URL
Contributors
Ramona Curpăn
(Author)
Sorin Avram
(Author)
Robert Vianello
(Author)
Cristian Bologa
(Author)
External identifiers
Added
2016-01-28
Last modified
2022-05-24
Source:
Crossref
Crossref
Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
2013-07-16 | Patent
Contributors:
Arterburn Jeffrey B; Bologa Cristian-george; Cimino Daniel F; Edwards Bruce S; Kiselyov Alexandor (and 6 more)
Show more detail
Homepage URL
Contributors
Arterburn Jeffrey B
(Other Inventor)
Bologa Cristian-george
(Other Inventor)
Cimino Daniel F
(Other Inventor)
Edwards Bruce S
(Other Inventor)
Kiselyov Alexandor
(Other Inventor)
Oprea Tudor I
(Other Inventor)
Prossnitz Eric R
(Other Inventor)
Revankar Chetana M
(Other Inventor)
Sklar Larry A
(Other Inventor)
Tkatchenko Sergey E
(Other Inventor)
Young Susan M
(Other Inventor)
External identifiers
LENSID:
146-384-947-655-000
URI:
lens.org/146-384-947-655-000
PAT:
US 8487100 B2
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
A Selective ATP-Binding Cassette Subfamily G Member 2 Efflux Inhibitor Revealed via High-Throughput Flow Cytometry
Source:
Web of Science
Web of Science
Cheminformatics aspects of high throughput screening: from robots to models: symposium summary
Source:
Web of Science
Web of Science
Emerging trends in the discovery of natural product antibacterials
Source:
Web of Science
Web of Science
Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters
Source:
Web of Science
Web of Science
The CARLSBAD Database: A Confederated Database of Chemical Bioactivities
Source:
Web of Science
Web of Science
A Novel Flow Cytometric HTS Assay Reveals Functional Modulators of ATP Binding Cassette Transporter ABCB6
Source:
Web of Science
Web of Science
Compound Collection Preparation for Virtual Screening
External identifiers
DOI:
10.1007/978-1-61779-965-5_7
ISSN:
1064-3745
ISBN:
978-1-61779-964-8
Added
2013-11-04
Last modified
2015-07-18
Source:
Crossref Metadata Search
Crossref Metadata Search
Identification of a Small Molecule Yeast TORC1 Inhibitor with a Multiplex Screen Based on Flow Cytometry
External identifiers
DOI:
10.1021/CB200452R
WOSUID:
WOS:000302977300014
Added
2026-08-12
Last modified
2026-08-12
Source:
Web of Science
Web of Science
Of possible cheminformatics futures
Source:
Web of Science
Web of Science
COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF
2011-04-21 | Patent
Contributors:
Arterburn Jeffrey B; Bologa Cristian-george; Cimino Daniel F; Edwards Bruce S; Kiselyov Alexander (and 6 more)
Show more detail
Homepage URL
Contributors
Arterburn Jeffrey B
(Other Inventor)
Bologa Cristian-george
(Other Inventor)
Cimino Daniel F
(Other Inventor)
Edwards Bruce S
(Other Inventor)
Kiselyov Alexander
(Other Inventor)
Oprea Tudor I
(Other Inventor)
Prossnitz Eric R
(Other Inventor)
Revankar Chetana M
(Other Inventor)
Sklar Larry A
(Other Inventor)
Tkatchenko Sergey E
(Other Inventor)
Young Susan M
(Other Inventor)
External identifiers
LENSID:
166-181-878-437-362
URI:
lens.org/166-181-878-437-362
PAT:
US 2011/0092533 A1
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
Abstract LB-214: Rac1 and Cdc42 GTPases as novel targets in ovarian cancer
Cancer Research
2011-04 | Journal article
Contributors:
A. Wandinger-Ness; S. R. Kenney; J. Agola; J. Roxby; Z. Surviladze (and 10 more)
Show more detail
Contributors
A. Wandinger-Ness
(Author)
S. R. Kenney
(Author)
J. Agola
(Author)
J. Roxby
(Author)
Z. Surviladze
(Author)
M. Silberberg
(Author)
R. Zeineldin
(Author)
A. Vestling
(Author)
C. Bologa
(Author)
O. Ursu
(Author)
T. Oprea
(Author)
C. Muller
(Author)
L. Lomo
(Author)
L. Sklar
(Author)
L. G. Hudson
(Author)
External identifiers
DOI:
10.1158/1538-7445.am2011-lb-214
Added
2016-03-29
Last modified
2022-05-24
Source:
Crossref Metadata Search
Crossref Metadata Search
Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
2011-01-25 | Patent
Contributors:
Arterburn Jeffrey B; Bologa Cristian-george; Cimino Daniel F; Edwards Bruce S; Kiselyov Alexander (and 6 more)
Show more detail
Homepage URL
Contributors
Arterburn Jeffrey B
(Other Inventor)
Bologa Cristian-george
(Other Inventor)
Cimino Daniel F
(Other Inventor)
Edwards Bruce S
(Other Inventor)
Kiselyov Alexander
(Other Inventor)
Oprea Tudor I
(Other Inventor)
Prossnitz Eric R
(Other Inventor)
Revankar Chetana M
(Other Inventor)
Sklar Larry A
(Other Inventor)
Tkatchenko Sergey E
(Other Inventor)
Young Susan M
(Other Inventor)
External identifiers
LENSID:
035-907-424-658-718
URI:
lens.org/035-907-424-658-718
PAT:
US 7875721 B2
Added
2026-08-12
Last modified
2026-08-15
Source:
The Lens
The Lens
Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing
Source:
Web of Science
Web of Science
Drug repurposing from an academic perspective
External identifiers
DOI:
10.1016/j.ddstr.2011.10.002
ISSN:
1740-6773
Added
2013-11-04
Last modified
2015-07-18
Source:
Crossref Metadata Search
Crossref Metadata Search
High-Throughput Screen for the Chemical Inhibitors of Antiapoptotic Bcl-2 Family Proteins by Multiplex Flow Cytometry
Source:
Web of Science
Web of Science
Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity
Source:
Web of Science
Web of Science
Microbial Efflux Pump Inhibition: Tactics and Strategies
Source:
Web of Science
Web of Science